- Home
- MD vs MNKD Comparison
MD vs MNKD Comparison
Compare MD & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MD
- MNKD
- Stock Information
- Founded
- MD 1979
- MNKD 1991
- Country
- MD United States
- MNKD United States
- Employees
- MD N/A
- MNKD N/A
- Industry
- MD Hospital/Nursing Management
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- MD Health Care
- MNKD Health Care
- Exchange
- MD Nasdaq
- MNKD Nasdaq
- Market Cap
- MD 1.1B
- MNKD 1.4B
- IPO Year
- MD 1995
- MNKD 2004
- Fundamental
- Price
- MD $14.53
- MNKD $4.56
- Analyst Decision
- MD Buy
- MNKD Buy
- Analyst Count
- MD 6
- MNKD 6
- Target Price
- MD $17.08
- MNKD $8.92
- AVG Volume (30 Days)
- MD 729.9K
- MNKD 1.5M
- Earning Date
- MD 05-06-2025
- MNKD 05-08-2025
- Dividend Yield
- MD N/A
- MNKD N/A
- EPS Growth
- MD N/A
- MNKD 215.86
- EPS
- MD N/A
- MNKD 0.10
- Revenue
- MD $1,976,177,000.00
- MNKD $297,595,000.00
- Revenue This Year
- MD N/A
- MNKD $14.23
- Revenue Next Year
- MD $2.76
- MNKD $14.56
- P/E Ratio
- MD N/A
- MNKD $46.04
- Revenue Growth
- MD N/A
- MNKD 32.50
- 52 Week Low
- MD $6.62
- MNKD $4.17
- 52 Week High
- MD $17.67
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- MD 63.62
- MNKD 38.80
- Support Level
- MD $12.17
- MNKD $4.42
- Resistance Level
- MD $12.95
- MNKD $5.05
- Average True Range (ATR)
- MD 0.52
- MNKD 0.18
- MACD
- MD 0.29
- MNKD 0.00
- Stochastic Oscillator
- MD 88.75
- MNKD 20.59
About MD Pediatrix Medical Group Inc.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.